Nilotinib hydrochloride anhydrous
Modify Date: 2024-01-19 14:16:09
Nilotinib hydrochloride anhydrous structure
|
Common Name | Nilotinib hydrochloride anhydrous | ||
|---|---|---|---|---|
| CAS Number | 923288-95-3 | Molecular Weight | 565.977 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C28H23ClF3N7O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Nilotinib hydrochloride anhydrousNilotinib (AMN107) hydrochlorid is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1][2][3]. |
| Name | 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide,hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Nilotinib (AMN107) hydrochlorid is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Nilotinib hydrochlorid, selective Abl inhibitor, is designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than imatinib while being significantly more potent compared with imatinib (IC50<30 nM), also maintains activity against most of the BCR-ABL point mutants that confer Imatinib resistance[1]. Nilotinib hydrochlorid demonstrates significant antitumor efficacy against GIST xenograft lines and imatinib-resistant GIST cell lines which parent cell lines GK1C and GK3C shows imatinib sensitivity with IC50 of 4.59±0.97 µM and 11.15±1.48 µM, respectively, imatinib-resistant cell lines GK1C-IR and GK3C-IR shows Imatinib resistance with IC50 values of 11.74±0.17 µM (P<0.001) and 41.37±1.07 µM (P<0.001), respectively[2]. |
| In Vivo | Nilotinib hydrochlorid (oral gavage, 40 mg/kg, daily, 4 weeks) shows equivalent or higher antitumor effects in BALB/cSLc-nu/nu mice with GIST xenograft[2]. Nilotinib hydrochlorid has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model while decreases the PDGFR α and β levels and apoptotic scores in the colon[3]. Animal Model: BALB/cSLc-nu/nu mice with GIST xenograft (GK1X, GK2X and GK3X)[2] Dosage: 40 mg/kg Administration: Oral gavage; daily; 4 weeks Result: Inhibited tumor growth by 69.6% in GK1X, 85.3% in GK2X and 47.5% in GK3X xenograft line. |
| References |
| Molecular Formula | C28H23ClF3N7O |
|---|---|
| Molecular Weight | 565.977 |
| Exact Mass | 565.160461 |
| PSA | 101.11000 |
| LogP | 7.61480 |
| Storage condition | -20℃ |
| Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-, hydrochloride (1:1) |
| 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluormethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzolcarboxamidhydrochlorid |
| 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide hydrochloride |
| Nilotinib hydrochloride anhydrous |
| X8407 |
| 4-méthyl-N-[3-(4-méthyl-1H-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide chlorhydrate |
| benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-, monohydrochloride |
| Nilotinib hydrochloride |
| 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}benzamide hydrochloride (1:1) |
| UNII-K37N7BYX3X |
| K37N7BYX3X |
| Nilotinib HCl |